TW202523329A - 阿立哌唑注射用製劑之投予方法 - Google Patents

阿立哌唑注射用製劑之投予方法 Download PDF

Info

Publication number
TW202523329A
TW202523329A TW113142852A TW113142852A TW202523329A TW 202523329 A TW202523329 A TW 202523329A TW 113142852 A TW113142852 A TW 113142852A TW 113142852 A TW113142852 A TW 113142852A TW 202523329 A TW202523329 A TW 202523329A
Authority
TW
Taiwan
Prior art keywords
aripiprazole
salt
patient
days
injection
Prior art date
Application number
TW113142852A
Other languages
English (en)
Chinese (zh)
Inventor
馬修 哈理
王曉峰
燕琳 王
阿拉什 羅歐芬尼安
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202523329(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202523329A publication Critical patent/TW202523329A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
TW113142852A 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法 TW202523329A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01

Publications (1)

Publication Number Publication Date
TW202523329A true TW202523329A (zh) 2025-06-16

Family

ID=75581573

Family Applications (3)

Application Number Title Priority Date Filing Date
TW113142852A TW202523329A (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法
TW110112185A TWI906279B (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法
TW110112186A TWI865760B (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110112185A TWI906279B (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法
TW110112186A TWI865760B (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法

Country Status (16)

Country Link
US (6) US20230129919A1 (https=)
EP (3) EP4467194A3 (https=)
JP (4) JP7733000B2 (https=)
KR (3) KR20220161402A (https=)
CN (3) CN115379842A (https=)
AU (2) AU2021248212A1 (https=)
BR (2) BR112022018721A2 (https=)
CA (3) CA3163321C (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012354A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TW202523329A (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére
CA3197997A1 (en) 2023-03-17 2025-01-23 Otsuka Pharmaceutical Co., Ltd. METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4082546A1 (en) 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére

Also Published As

Publication number Publication date
JP2025020306A (ja) 2025-02-12
EP3941470A1 (en) 2022-01-26
KR20240165486A (ko) 2024-11-22
JP7733000B2 (ja) 2025-09-02
EP4467194A3 (en) 2025-01-08
JP7584535B2 (ja) 2024-11-15
US20220160621A1 (en) 2022-05-26
MX2022012353A (es) 2022-10-31
KR102732030B1 (ko) 2024-11-20
AU2021248212A1 (en) 2022-12-01
CA3212191A1 (en) 2021-10-07
CA3163321C (en) 2023-12-19
CN115379842A (zh) 2022-11-22
EP4467194A2 (en) 2024-11-27
CA3163321A1 (en) 2021-10-07
WO2021201239A1 (en) 2021-10-07
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
US20240374506A1 (en) 2024-11-14
EP4125903B1 (en) 2024-10-09
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
CN115397420A (zh) 2022-11-25
US20230129919A1 (en) 2023-04-27
TWI865760B (zh) 2024-12-11
KR20220161402A (ko) 2022-12-06
US20260115131A1 (en) 2026-04-30
JP2023520004A (ja) 2023-05-15
EP4125903C0 (en) 2024-10-09
JP2023519425A (ja) 2023-05-10
TW202200141A (zh) 2022-01-01
JP2025176037A (ja) 2025-12-03
US20260034053A1 (en) 2026-02-05
TWI906279B (zh) 2025-12-01
EP4125903A1 (en) 2023-02-08
PL4125903T3 (pl) 2025-02-03
BR112022018721A2 (pt) 2022-11-01
AU2021245713A1 (en) 2022-12-01
HUE069157T2 (hu) 2025-02-28
US20230225962A1 (en) 2023-07-20
WO2021201238A1 (en) 2021-10-07
ES2995466T3 (en) 2025-02-10
CA3136727A1 (en) 2021-10-07
MX2022012354A (es) 2022-10-31
CN119792290A (zh) 2025-04-11
BR112022018647A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
TWI865760B (zh) 阿立哌唑注射用製劑之投予方法
US11344547B2 (en) Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP6353577B2 (ja) 組み合わせ組成物
KR102794804B1 (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
EP3785698A1 (en) Edaravone pharmaceutical composition
SG193391A1 (en) A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide
JP2023552149A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
AU2015323321A1 (en) Long acting pharmaceutical compositions
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
KR20100124860A (ko) 독소필린을 포함하는 변형 방출 조성물
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
EP4647082A1 (en) Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
CN107921023A (zh) 用于治疗偏头痛的包含舒马曲坦的药物组合物
EA050359B1 (ru) Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer